-
公开(公告)号：US20200271667A1
公开(公告)日：2020-08-27
申请号：US16646639
申请日：2018-09-13
Applicant: B.R.A.H.M.S GmbH
Inventor： Darius WILSON
Abstract: The invention relates to a method of therapy guidance, stratification and/or monitoring of fluid therapy based on proadrenomedullin (proADM) levels. The invention therefore relates to a method for therapy guidance, stratification and/or monitoring of a fluid therapy, comprising providing a sample of said patient, determining a level of pro adrenomedullin (proADM) or fragment(s) thereof in said sample, wherein said level of proADM or fragment(s) thereof indicates the prescription of fluid therapy to be administered to the patient. The invention further relates to methods for guiding fluid therapy volume and to methods of treating disease using fluid therapy based on the proADM stratification of patients based on the methods described herein.
-
公开(公告)号：US20220221474A1
公开(公告)日：2022-07-14
申请号：US17710329
申请日：2022-03-31
Applicant: B.R.A.H.M.S GmbH
Inventor： Aline PEHLA , Stefan KIRSCH , Darius WILSON
Abstract: The invention relates to a method for determining, diagnosis, prognosis, treatment guidance, treatment monitoring, risk assessment and/or risk stratification of patients with abnormal platelet levels comprising providing a sample of said patient, determining a level of proadrenomedullin (proADM) or fragment(s) thereof in said sample, wherein said level of proADM or fragment(s) thereof correlates with the abnormal platelet levels in said patient. In embodiments of the invention, a level of proADM or fragment(s) thereof of high severity indicates low platelet levels in the subject and subsequent initiating or modifying a treatment of the patient to improve said condition. In some embodiments of the invention the method comprises determining a level of one or more additional markers in a sample isolated from the patient, such as the level of platelets, the level of PCT or fragment(s) thereof, one or more markers of thrombocytopenia and/or one or more markers of an inflammatory response.
-
公开(公告)号：US20210109117A1
公开(公告)日：2021-04-15
申请号：US16956036
申请日：2018-12-20
Applicant: B.R.A.H.M.S GmbH
Inventor： Aline PEHLA , Darius WILSON
IPC: G01N33/74
Abstract: The present invention is in the field of clinical diagnostics. Particularly, the present invention relates to the assessment of severity of a subject being suspected of an infection or having an infection, who may have physiological signs or increased risk factors for infection, in particular from an infectious disease by determination of the levels of Procalcitonin (hereinafter: PCT) (SEQ ID No: 1 and/or proadrenomedullin (hereinafter: proADM)) (SEQ ID No: 3) or a partial peptide or fragment thereof, in particular midregional proadrenomedullin (MR-proADM) (SEQ ID No: 2), in a sample of a patient and the invention is related to a workflow hereto. Moreover, the invention refers to the assessment related to an infection like ruling out/in a patient and stratification, risk assessment, in particular to avoid rehospitalisation and hospital and post-discharge mortality.
-
公开(公告)号：US20240393352A1
公开(公告)日：2024-11-28
申请号：US18792888
申请日：2024-08-02
Applicant: B.R.A.H.M.S GMBH
Inventor： Darius WILSON , Stefan KIRSCH
Abstract: A method for sample preparation for antibiotic therapy guidance, stratification and/or control in a patient with one or more comorbidities comprising an impaired innate immune response and suspected of having an infection. Also, a method for sample preparation for antibiotic therapy guidance, stratification and/or control in a patient with one or more comorbidities comprising an impaired innate immune response. The method comprises providing a sample from said patient and determining a level of PCT or fragment(s) thereof in said sample, wherein the level of PCT or fragment(s) thereof in said sample is indicative of whether an initiation or a change of an antibiotic treatment is required.
-
公开(公告)号：US20200300864A1
公开(公告)日：2020-09-24
申请号：US16646637
申请日：2018-09-13
Applicant: B.R.A.H.M.S GMBH
Inventor： Darius WILSON
IPC: G01N33/68
Abstract: A method for therapy monitoring, comprising: the prognosis, risk assessment and/or risk stratification of a subsequent adverse event in the health of a patient; providing a sample of said patient, wherein the patient was diagnosed as critically ill and medical treatment initiated, wherein the sample is isolated from the patient after diagnosis and treatment initiation; determining a level of proADM or fragment(s) thereof in said sample, wherein said level of proADM or fragment(s) thereof correlates with the likelihood of a subsequent adverse event in the health of said patient. In a preferred embodiment the invention relates to a method comprising additionally determining a level of procalcitonin (PCT) or fragment(s) thereof in a sample isolated from the patient. Optionally, further determining a level of PCT or fragment(s) thereof in samples isolated from the patient and using the PCT levels also in the prognosis, risk assessment and/or risk stratification.
-
Patent Agency Ranking
公开(公告)号：US20210109118A1
公开(公告)日：2021-04-15
申请号：US16956046
申请日：2018-12-20
Applicant: B.R.A.H.M.S GmbH
Inventor： Darius WILSON
IPC: G01N33/74
Abstract: The invention relates to a method for antibiotic therapy guidance, stratification and/or control in a patient suspected of having an infection. In particular, the method comprises providing a sample form said patient, determining a level of proADM or fragment(s) thereof in said sample, and wherein the level of proADM or fragment(s) thereof in said sample is indicative of whether an initiation or a change of an antibiotic treatment is required. In a preferred embodiment of the invention, the method comprises additionally determining in a sample from said patient a level of PCT or fragment(s) thereof. Furthermore, the invention also relates to a kit for carrying out the method of the present invention.
-
公开(公告)号：US20200319212A1
公开(公告)日：2020-10-08
申请号：US16956330
申请日：2018-12-20
Applicant: B.R.A.H.M.S GMBH
Inventor： Darius WILSON , Stefan KIRSCH
Abstract: A method for antibiotic therapy guidance, stratification and/or control in a patient with one or more comorbidities comprising an impaired innate immune response and suspected of having an infection. Also, a method for antibiotic therapy guidance, stratification and/or control in a patient with one or more comorbidities comprising an impaired innate immune response, wherein the comorbidity is preferably selected from the group comprising metabolic disorder (obesity), diabetes, hypertension, renal disease, thrombosis, malignancy or cancer, and suspected of having an infection. In particular, the method comprises providing a sample from said patient and determining a level of PCT or fragment(s) thereof in said sample, wherein the level of PCT or fragment(s) thereof in said sample is indicative of whether an initiation or a change of an antibiotic treatment is required. Furthermore, a kit for carrying out the method of the present invention.
-
公开(公告)号：US20200271675A1
公开(公告)日：2020-08-27
申请号：US16646798
申请日：2018-09-13
Applicant: B.R.A.H.M.S GmbH
Inventor： Aline PEHLA , Stefan KIRSCH , Darius WILSON
Abstract: The invention relates to a method for determining, diagnosis, prognosis, treatment guidance, treatment monitoring, risk assessment and/or risk stratification of patients with abnormal platelet levels comprising providing a sample of said patient, determining a level of proadrenomedullin (proADM) or fragment(s) thereof in said sample, wherein said level of proADM or fragment(s) thereof correlates with the abnormal platelet levels in said patient. In embodiments of the invention, a level of proADM or fragment(s) thereof of high severity indicates low platelet levels in the subject and subsequent initiating or modifying a treatment of the patient to improve said condition. In some embodiments of the invention the method comprises determining a level of one or more additional markers in a sample isolated from the patient, such as the level of platelets, the level of PCT or fragment(s) thereof, one or more markers of thrombocytopenia and/or one or more markers of an inflammatory response.
-
9.发明申请公开(公告)号：US20200271666A1
公开(公告)日：2020-08-27
申请号：US16646495
申请日：2018-09-13
Applicant: B.R.A.H.M.S GmbH
Inventor： Darius WILSON
IPC: G01N33/68
Abstract: The present invention relates to a method for assessing whether a critically ill subject is in need of a renal replacement therapy, wherein the method comprises determining in a sample obtained from said subject the level of proadrenomedullin (proADM) or a fragment thereof, preferably the fragment is MR-proADM, wherein said level of proADM or the fragment thereof is indicative of a need of said subject to receive a renal replacement therapy.
-
公开(公告)号：US20200264199A1
公开(公告)日：2020-08-20
申请号：US16646799
申请日：2018-09-13
Applicant: B.R.A.H.M.S GmbH
Inventor： Darius WILSON
IPC: G01N33/74
Abstract: A method for antibiotic therapy guidance, stratification and/or control in a patient suffering from an infectious disease and receiving treatment with one or more antibiotic agents. The method comprises isolating a first and subsequently second sample from said patient and initiating antibiotic treatment, determining levels of procalcitonin (PCT) or fragment(s) thereof in both samples, and determining a level of proadrenomedullin (proADM) or fragment(s) thereof in at least the second sample, wherein the levels of PCT or fragment(s) thereof in said samples, and the level of proADM or fragment(s) thereof in the second sample, indicate whether a change in the treatment with one or more antibiotic agents is required. The method may comprise additionally determining a level of proADM or fragment(s) thereof in the first sample. Changes in the proADM and PCT levels between the first and second samples may indicate a need for changing the antibiotic treatment.
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.011 seconds)
